Core Viewpoint - Cathay Securities has initiated coverage on China Biologic Products (01177) with a "Buy" rating and a target price of HKD 10, forecasting earnings per share of RMB 0.293, 0.259, and 0.283 for the years 2025 to 2027 respectively [1] Group 1: Industry Overview - The investment sentiment in the healthcare sector in mainland China has significantly rebounded over the past year, positioning China Biologic Products favorably within this trend [1] - The company is recognized as one of the largest and best-developed pharmaceutical enterprises in China, with strong capabilities in scale, financing, and commercial infrastructure [1] Group 2: Company Strategy and Development - China Biologic Products has increased its investment in business development, rapidly expanding its portfolio of innovative drugs [1] - The company is expected to have several key catalysts and potential product approvals on the horizon, which will add new value to its innovative pipeline [1] - Important clinical data is anticipated to be released soon, which is likely to accelerate the progress of its innovative research and development [1]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - China's rich pool of engineers and scientists, along with efficient and cost-effective clinical trials and drug manufacturing capabilities, are seen as core competitive advantages for pharmaceutical innovation [2] - The impact of the US imposing tariffs on innovative drugs is expected to be limited for the CXO sector, as many multinational pharmaceutical companies already have plans to build factories in the US [2] - Future growth in innovative drugs is anticipated to be driven by overseas partners pushing clinical development for licensed pipelines [2]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]

Core Viewpoint - The MSCI China Healthcare Index has increased by 74.0% year-to-date, outperforming the MSCI China Index by 37.3% [1] Group 1: Market Trends - The recovery in capital market financing and the increase in overseas trading scale for innovative drugs have led to a rebound in domestic innovative drug research and development demand [1] - The CXO industry is expected to see performance recovery in the second half of the year due to the impact of U.S. interest rate cuts [1] Group 2: Regulatory Impact - The anticipated increase in tariffs on innovative drugs by the U.S. is expected to have a limited impact on the CXO sector [1] - Many multinational pharmaceutical companies already have plans to establish factories in the U.S., which may mitigate potential negative effects [1] Group 3: Future Outlook - The ongoing upward momentum for innovative drugs is expected to primarily come from overseas partners driving clinical progress for authorized pipelines [1] - There is optimism regarding valuation recovery opportunities in consumer healthcare, with recommendations to buy stocks in companies such as 3SBio, Junshi Biosciences, WuXi AppTec, Genscript Biotech, China National Pharmaceutical Group, and Innovent Biologics [1]

Group 1 - The core viewpoint of the reports indicates a recovery in domestic innovative drug research and development due to the resurgence of capital market financing and an increase in overseas transactions for innovative drugs [1] - The price of experimental monkeys, essential for innovative drug research, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] - The CXO industry is expected to see performance recovery in the second half of 2025, driven by the continuous upward momentum of innovative drugs primarily from overseas partners pushing clinical pipelines [1] Group 2 - The report highlights a shift in global early-stage drug innovation research from Europe and the US to China, with multinational pharmaceutical companies increasingly sourcing innovative pipelines from Chinese biotech firms [1] - The proposed administrative order by the Trump administration to restrict the import of experimental treatments from China has sparked intense lobbying from two opposing groups: US biotech investors facing competition from Chinese innovations and large pharmaceutical companies benefiting from low-cost Chinese drugs [1] - The report emphasizes that the income and profit scale of large US pharmaceutical companies far exceed that of US biotech firms, suggesting they may have greater lobbying influence [1] Group 3 - The announcement of a 100% tariff on patented drugs unless pharmaceutical companies build factories in the US is expected to have a limited impact on the CXO sector, as many multinational companies already have plans to establish facilities in the US [2] - Significant investment plans have been announced by several multinational pharmaceutical companies for building factories and R&D facilities in the US, including Eli Lilly's $27 billion and Roche's $50 billion investments over the next five years [2] - The report notes that the construction of factories in the US typically takes over five years, and the progress may be affected by political and market uncertainties [2]

Group 1 - Tencent Holdings (00700) leads the net inflow with 2.642 billion, representing a 22.29% increase in share price [1][2] - Sunac China Holdings (00412) follows with a net inflow of 889 million, but its share price decreased by 6.00% [1][2] - SMIC (00981) has a net inflow of 684 million, with a share price increase of 5.72% [1][2] Group 2 - Hong Kong Exchanges and Clearing (00388) experiences the highest net outflow at -351 million, with a slight share price increase of 0.18% [1][2] - ZTE Corporation (00763) has a net outflow of -299 million, with a share price decrease of 0.18% [1][2] - China Biologic Products Holdings (01177) sees a net outflow of -210 million, with a share price decline of 1.72% [1][2] Group 3 - Weilu Group (01196) has the highest net inflow ratio at 68.77% [1][3] - Jiangsu Nanjing Highway (00177) follows with a net inflow ratio of 62.76% [1][3] - Air China (00753) ranks third with a net inflow ratio of 54.19% [1][3] Group 4 - Guangzhou-Shenzhen Railway (00525) has the highest net outflow ratio at -50.24% [1][3] - China Unicom (00762) follows with a net outflow ratio of -41.90% [1][3] - China Telecom (00728) ranks third with a net outflow ratio of -35.91% [1][3]

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1177） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, Sino Biopharmaceutical Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.sinobiopharm.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock ...

(Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1177） NOTIFICATION LETTER 通知信函 Dear Registered Shareholders, 26 September 2025 Sino Biopharmaceutical Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.sinobiopharm.com and the website of The Stock Exchange of Hong Kong Limit ...

SINO BIOPHARMACEUTICAL LIMITED ( 於開曼群島註冊成立之有限公司) (股票編號：1177) 中期報告 2025 Interim Report 2025 中期報告 公司資料 公司法定名稱 中國生物製藥有限公司 股票代號 1177 公司網址 www.sinobiopharm.com 公司註冊地點 開曼群島 主板上市日期 二零零三年十二月八日 創業板上市日期 二零零零年九月二十九日 董事 執行董事 謝其潤女士 （主席） 謝炳先生 （資深副主席） 鄭翔玲女士 （副主席） 謝承潤先生 （首席執行長） 謝炘先生 田舟山先生 獨立非執行董事 陸正飛先生 李大魁先生 魯紅女士 張魯夫先生 李國棟醫生 執行董事委員會 謝其潤女士 （主席） 謝炳先生 鄭翔玲女士 謝承潤先生 謝炘先生 審核委員會 陸正飛先生 （主席） 李大魁先生 魯紅女士 李國棟醫生 薪酬委員會 張魯夫先生 （主席） 陸正飛先生 魯紅女士 提名委員會 謝其潤女士 （主席） 謝炳先生 陸正飛先生 魯紅女士 張魯夫先生 李國棟醫生 環境、社會及管治委員會 鄭翔玲女士 （主席） 謝其潤女士 李國棟醫生 公司秘書 陳凱年先生 授權代表 謝炳 ...

Major Events - China Railway (00390) recently won bids for 11 major projects, with a total contract value of approximately 50.215 billion yuan [1] - China Communications Technology (03969) secured four important projects in the railway market from July to August [1] - Chow Tai Fook (00659) plans to issue convertible bonds worth 2.218 billion HKD, converting approximately 10% of shares in First Journey Holdings (00697) [1] - Shanghai Pharmaceuticals (02607) transferred 40% equity of Shanghai Pharmaceuticals Group to Shanghai Shansi for about 6.7215 billion yuan [1] - Tianjin Port Development (03382) plans to invest 95.403 million yuan to acquire 5% equity in Eurasia International [1] - Tianjin Port Development (03382) intends to acquire 40% equity in Alliance International for 723 million yuan, increasing its stake to 100% [1] - First Journey Holdings (00697) received investment from Beijing Robotics Fund in Quan Zhi Bo, continuing to increase investment in the robotics industry [1] - Boleton (01333) signed a strategic cooperation agreement with Mingyang Mining to promote the electrification and intelligence of mining transportation [1] - China Biopharmaceutical (01177) completed the first patient enrollment in the Phase I clinical trial of LM-350 "CDH17 ADC" in Australia [1] - Xinjiang Xinmin Mining (03833) proposed to issue A-shares [1] - Jihong Co., Ltd. (02603) expects a year-on-year increase of 55%-65% in net profit attributable to shareholders for the first three quarters [1] Buybacks and Shareholding Changes - Tencent Holdings (00700) repurchased 844,000 shares for 550 million HKD on September 25 [1] - Midea Group (00300) repurchased 2.0 billion yuan worth of 2.7455 million A-shares on September 25 [1] - Anta Sports (02020) repurchased 99.819 million HKD worth of 106,500 shares on September 25 [1] - Guoquan (02517) plans to use up to 100 million HKD for further repurchase of H-shares [1] - Juzi Holding increased its stake by acquiring 1.15 million shares in Giant Bio (02367) [1] - Harmony Health, a shareholder of Goldwind Technology (02208), reduced its holdings by approximately 57.14185 million shares [1]